journal article·2026-04

Elesclomol‐Loaded Cuprous Oxide Nanozymes with Dual‐Enzyme Activities for Implant‐Related Infection Therapy by Enhancing Bacterial Cuproptosis‐Like Death

Erxu Tao, Yiwei Sun, Yaxin Liu, Cailiang Shen, Yuanyin Wang, Xianwen Wang

Advanced Functional Materials· Volume 36· Issue 34
Publisher page

Abstract

ABSTRACT Implant‐related infections mediated by bacterial biofilm colonization remain a predominant contributor to orthopedic prosthesis failure. While conventional high‐dose antibiotic regimens frequently demonstrate limited clinical efficacy, often necessitating prosthesis replacement postdebridement, such interventions impose substantial psychological and financial burdens on patients. To address this challenge, ES@Cu 2 O nanozymes with dual‐enzyme activities were engineered by integrating cuprous oxide nanoparticles (Cu 2 O NPs) with the copper ionophore elesclomol (ES), aiming to combat implant‐related infections through enhanced cuproptosis‐like death. ES@Cu 2 O nanozymes exploit peroxidase‐like (POD‐like) activity to catalyze the conversion of endogenous hydrogen peroxide (H 2 O 2 ) into reactive oxygen species (ROS), generating a potent oxidative surge within the biofilm microenvironment. Concurrently, the glutathione‐peroxidase‐like (GSH‐Px‐like) activity of ES@Cu 2 O effectively depletes overexpressed glutathione (GSH), thereby increasing the ROS‐mediated therapeutic efficacy. Notably, ES exacerbates aberrant intracellular Cu 2 + accumulation, intensifying cuproptosis‐like death. Compared with the Cu 2 O treatment group, the ES@Cu 2 O treatment group demonstrated significantly greater antibacterial and biofilm eradication capabilities in vitro. RNA sequencing (RNA‐seq) revealed that in the ES@Cu 2 O treatment group, key energy metabolism pathways, including the TCA cycle, pyruvate metabolism, and oxidative phosphorylation, were substantially suppressed relative to those in the Cu 2 O treatment group, supporting the mechanism that ES‐mediated Cu 2 + overload potently enhances cuproptosis‐like death. In vivo, ES@Cu 2 O exhibited excellent antibacterial and restorative effects in mouse implant‐related infection models, while biosafety assessments confirmed its negligible systemic toxicity. Overall, this study revealed that the ES@Cu 2 O nanozymes with dual‐enzyme activities robustly eliminate biofilms and eradicate colonized bacteria in implant‐related infections by enhancing cuproptosis‐like death, suggesting a novel therapeutic strategy with significant potential for clinical translation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopedics The First Affiliated Hospital of Anhui Medical University Anhui Medical University Hefei P. R. China

Department of Orthopedics Institute of Orthopaedics Research Center for Translational Medicine The Second Affiliated Hospital of Anhui Medical University Anhui Medical University Hefei P. R. China

Key Lab. of Oral Diseases Research of Anhui Province College and Hospital of Stomatology Anhui Medical University Hefei P. R. China

School of Biomedical Engineering Anhui Medical University Hefei P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Anhui Province

References (49)

Show source-provided references
1. 10.1038/s41579‐018‐0019‐y10.1038/s41579‐018‐0019‐y ↗
2. 10.1016/j.biomaterials.2007.07.01310.1016/j.biomaterials.2007.07.013 ↗
3. 10.1016/j.jconrel.2020.06.01410.1016/j.jconrel.2020.06.014 ↗
4. 10.1016/S0140‐6736(14)61798‐010.1016/S0140‐6736(14)61798‐0 ↗
5. 10.1073/pnas.161372211310.1073/pnas.1613722113 ↗
6. 10.1126/science.284.5418.131810.1126/science.284.5418.1318 ↗
7. 10.1002/adma.20230473810.1002/adma.202304738 ↗
8. 10.1016/j.biomaterials.2012.05.03110.1016/j.biomaterials.2012.05.031 ↗
9. 10.1002/adma.20230343210.1002/adma.202303432 ↗
10. 10.1039/C7CS00807D10.1039/C7CS00807D ↗
11. 10.15252/embr.20205103410.15252/embr.202051034 ↗
12. 10.1002/adfm.20231181210.1002/adfm.202311812 ↗
13. 10.1002/smll.20220622010.1002/smll.202206220 ↗
14. 10.1016/j.bioactmat.2022.02.00310.1016/j.bioactmat.2022.02.003 ↗
15. 10.1016/S0140‐6736(01)05321‐110.1016/S0140‐6736(01)05321‐1 ↗
16. 10.1016/j.tibtech.2018.10.01110.1016/j.tibtech.2018.10.011 ↗
17. 10.1016/j.actbio.2023.05.04810.1016/j.actbio.2023.05.048 ↗
18. 10.1016/j.actbio.2023.10.02810.1016/j.actbio.2023.10.028 ↗
19. 10.1002/adhm.20247005110.1002/adhm.202470051 ↗
20. 10.1002/adfm.20241577810.1002/adfm.202415778 ↗
21. 10.1021/acsnano.4c0282510.1021/acsnano.4c02825 ↗
22. 10.1021/acsnano.4c0656510.1021/acsnano.4c06565 ↗
23. 10.1021/acsami.9b1009610.1021/acsami.9b10096 ↗
24. 10.1002/smll.20240719510.1002/smll.202407195 ↗
25. 10.1002/adma.20180536810.1002/adma.201805368 ↗
26. 10.1016/j.chom.2019.06.00410.1016/j.chom.2019.06.004 ↗
27. 10.1021/acs.accounts.8b0001110.1021/acs.accounts.8b00011 ↗
28. 10.1002/adma.20220796110.1002/adma.202207961 ↗
29. 10.1002/advs.20230169410.1002/advs.202301694 ↗
30. 10.1002/adma.20221104110.1002/adma.202211041 ↗
31. 10.1039/C8CS00457A10.1039/C8CS00457A ↗
32. 10.1039/c3cs35486e10.1039/c3cs35486e ↗
33. 10.1002/adma.20190410610.1002/adma.201904106 ↗
34. 10.1002/adma.20221045510.1002/adma.202210455 ↗
35. 10.1002/adma.20221121010.1002/adma.202211210 ↗
36. 10.1002/adhm.20230202310.1002/adhm.202302023 ↗
37. 10.1021/acs.nanolett.9b0224210.1021/acs.nanolett.9b02242 ↗
38. 10.1002/advs.20230582310.1002/advs.202305823 ↗
39. 10.1021/acsnano.4c0215710.1021/acsnano.4c02157 ↗
40. 10.1016/j.nantod.2022.10138010.1016/j.nantod.2022.101380 ↗
41. 10.1038/s41467‐022‐35050‐610.1038/s41467‐022‐35050‐6 ↗
42. 10.1126/science.abf052910.1126/science.abf0529 ↗
43. 10.1002/adma.20240595310.1002/adma.202405953 ↗
44. 10.1016/j.scib.2021.03.00310.1016/j.scib.2021.03.003 ↗
45. 10.1002/smll.20240680210.1002/smll.202406802 ↗
46. 10.1016/j.cell.2024.08.01810.1016/j.cell.2024.08.018 ↗
47. 10.1016/j.redox.2023.10289110.1016/j.redox.2023.102891 ↗
48. 10.1021/acsnano.3c0887510.1021/acsnano.3c08875 ↗
49. 10.1038/s41571‐024‐00876‐010.1038/s41571‐024‐00876‐0 ↗